

## Recommendations of the National Comprehensive Cancer Network® (NCCN®) COVID-19 Vaccination Advisory Committee\*

- Patients with active cancer and those on treatment should be prioritized for vaccination and should be immunized when any vaccine that has been authorized for use by the FDA is available to them.
- Immunization is recommended for all patients receiving active therapy, with the understanding that there are emerging efficacy data in these patients.
- Reasons for delay of vaccines are similar to those that impede delivery to the general public (e.g. recent exposure to COVID-19), and there are also cancer-specific factors. Vaccination should be delayed for at least 3 months following hematopoietic cell transplantation (HCT) or engineered cellular therapy (e.g. chimeric antigen receptor [CAR] T-cells) to maximize vaccine efficacy.
- Eligible caregivers and household/close contacts should be immunized whenever possible.
- The committee supports use of any of the available FDA approved or EUA approved vaccines (Pfizer/BioNTech [BNT162b2 mRNA vaccine], Moderna [mRNA-1273 SARS-CoV-2 Vaccine] and Janssen/Johnson & Johnson [Ad26.COVS.2 Adenovirus vector vaccine]) in patients who are eligible.
- The committee supports mandates for healthcare workers that require vaccination.

**Table 1. COVID-19 Vaccination Recommendations for Cancer Patients\*\***

(see next section for details on third doses)

Patients Treatment/Cancer Type	Timing <sup>†,‡,¶</sup>
<b>Hematopoietic Cell Transplantation (HCT)/Cellular Therapy</b>	
Allogeneic transplantation Autologous transplantation Cellular therapy (e.g. CAR T-cell)	At least 3 months post-HCT/cellular therapy <sup>a,b</sup>
<b>Hematologic Malignancies</b>	
Receiving intensive cytotoxic chemotherapy (e.g. cytarabine/anthracycline-based induction regimens for acute myeloid leukemia)	Delay until absolute neutrophil count (ANC) recovery <sup>c</sup>
Marrow failure from disease and/or therapy expected to have limited or no recovery	When vaccine available
Long-term maintenance therapy (e.g. targeted agents for chronic lymphocytic leukemia or myeloproliferative neoplasms)	When vaccine available <sup>c</sup>
<b>Solid Tumor Malignancies</b>	
Receiving cytotoxic chemotherapy	When vaccine available <sup>c,d</sup>
Targeted therapy	When vaccine available
Checkpoint inhibitors and other immunotherapy	When vaccine available <sup>e</sup>
Radiation	When vaccine available
Major surgery	Separate date of surgery from vaccination by at least a few days <sup>f</sup>
<b>Caregivers and Household/Close Contacts</b>	
Any time eligible to receive the vaccine <sup>g</sup>	

\*\*The Pfizer/BioNTech mRNA vaccine is FDA approved for ≥16 years of age; it remains under EUA for age 12-15

The Moderna and Janssen/Johnson & Johnson vaccines are approved under EUA for ≥18 years of age

†COVID-19 vaccines and other vaccines may now be administered without regard to timing. This include simultaneous administration of COVID-19 vaccine and other vaccines on the same day, as well as coadministration within 14 days.<sup>36</sup>

‡ In rare instances, clinical trials (e.g., involving anti-cancer vaccines) may exclude or require modification of timing of standard of care vaccines, including COVID-19 vaccines. This should be discussed with clinical trial investigators to ensure that the COVID-19 vaccine is initiated as soon as feasible.

¶ CDC recommendations for timing of vaccination post-COVID-19 infection (after removal from isolation [minimum  $\geq 20$  days for cancer patients]), and/or post-SARS-CoV-2-specific monoclonal antibody or SARS-CoV-2 convalescent plasma (after 90-days).

---

### Table Footnotes

- a) Graft-versus-host disease (GVHD) and immunosuppressive regimens to treat GVHD (e.g. systemic corticosteroids and targeted agents) are expected to blunt immune responses to vaccination. Delay of vaccination until immunosuppressive therapy is reduced and/or based on immunophenotyping of T-cell and B-cell immunity can be considered.
- b) Patients on maintenance therapies (e.g. rituximab, Bruton tyrosine kinase inhibitors, Janus kinase inhibitors) may have attenuated response to vaccination (see below).
- c) The committee recognizes that granulocytopenia does not, in itself, significantly affect immunologic response to vaccination. It is used in this setting of profound immunosuppression for patients with hematologic malignancies as a surrogate marker for recovery of adequate immunocompetence to respond to vaccines and sufficient platelet recovery to avoid bleeding complications from intramuscular administration. Due to short periods of neutropenia among solid tumor malignancies this is not used for timing of vaccination.
- d) In patients receiving chemotherapy, optimal timing of vaccination in relation to cycles of chemotherapy is unknown. Given the variability of specific regimens and intervals between cycles, it is not possible to state whether immunization will be more effective if administered at the time of chemotherapy administration versus mid-cycle when the white blood cell (WBC) count might be at its nadir. In the absence of data, we recommend vaccination when available.
- e) There may be theoretical risk of exacerbated immune-related adverse events in patients receiving immune checkpoint inhibitors, but early data so far has not demonstrated such findings.<sup>23</sup> There are no data on timing of vaccine administration, so this may be considered on the same day as immunotherapy for convenience and to reduce added visits to the office whenever possible.
- f) The primary reason for avoiding vaccine in the perioperative period is so that symptoms (e.g. fever) can be correctly attributed to surgery versus vaccination. For more complex surgeries (e.g. splenectomy or which may lead to an immunosuppressive state), surgeons may recommend a wider window (+/- 2 weeks) from the time of surgery.
- g) Even if vaccinated, close contacts should continue to wear masks, maintain social distancing guidelines, and follow other CDC recommendations for COVID-19 prevention.

**THIRD DOSE RECOMMENDATIONS:**

The FDA issued an update to the emergency use authorization (EUA) for the Pfizer-BioNTech mRNA vaccine (Comirnaty®) and the Moderna mRNA vaccine to include an additional dose after an initial 2-dose series for moderately to severely immunocompromised patients. The amendment only applies to mRNA COVID-19 vaccines because there are insufficient data on an additional dose of the Janssen/Johnson & Johnson COVID-19 vaccine. This most recent update to the EUA was based on a growing body of literature showing that immunocompromised patients can have impaired immune responses to vaccination. Limited data in solid organ transplant recipients show a substantial effect of an additional dose in augmenting antibody responses to vaccination after completion of a 2-dose series.<sup>1</sup>

The CDC recently recommended a third dose of the mRNA vaccines for moderately to severely immunocompromised people, defined as:

- Been receiving active cancer treatment for tumors or cancers of the blood
- Received an organ transplant and are taking medicine to suppress the immune system
- Received a stem cell transplant within the last 2 years or are taking medicine to suppress the immune system
- Moderate or severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome)
- Advanced or untreated HIV infection
- Active treatment with high-dose corticosteroids or other drugs that may suppress your immune response

The NCCN COVID-19 vaccination committee fully supports a third dose for immunocompromised patients. Below, we provide consensus recommendations on patients with cancer who should be prioritized for a third dose.

- a) **Solid tumor malignancies:** We recommend a third dose for patients who received cancer therapy within 1-year of the initial vaccine administration. Realizing that specific therapies have different effects on the immune system, this recommendation applies to all cancer therapies, including but not limited to chemotherapy, targeted therapy, immunotherapy, hormonal therapy, surgery, radiation, and investigational agents. These criteria do not apply to non-melanoma skin cancers or superficial mucosal lesions treated solely with local therapy. In addition, patients with newly diagnosed cancer or recurrent cancer who will receive cancer therapy are included among patients prioritized for a third dose.
- b) **Hematologic malignancies:** We recommend that all patients with active hematologic malignancies receive a third dose regardless of whether they are receiving cancer therapy. The reason for this recommendation is that patients with hematologic malignancies are at high risk for poor serologic responses to vaccination both as a result of immunodeficiency due to the malignancy and their associated cancer therapies (e.g. B-cell-depleting agents such as anti-CD20 antibodies and Bruton tyrosine kinase inhibitors).<sup>2-10</sup> As examples, patients with Hodgkin's and Non-Hodgkin's lymphoma, chronic lymphocytic leukemia, multiple myeloma, myelodysplastic syndrome, or chronic myeloproliferative neoplasms should be prioritized for a third dose even if not on active therapy for these malignancies.
- c) **Hematopoietic cell transplant and cellular therapy:** We recommend a third dose in stem cell transplant (SCT) recipients and those who received engineered cellular therapy (e.g. CAR T-cells), prioritizing those who are ≤ 2 years post-procedure. A third dose is recommended for all

allogeneic SCT recipients who are actively receiving immunosuppressive therapy or with a history of graft-versus-host disease (GvHD) regardless of the time post-transplant.

- d) **Cancer and other immunosuppressive conditions that do not meet other criteria:** We recommend a third dose for patients with cancer who have other concurrent immunocompromising conditions, such as HIV infection or autoimmune diseases. In addition, patients with cancer treated with systemic corticosteroids and other immunosuppressive agents separate from cancer therapy should be prioritized for a third dose.

#### **Timing of Administration of Third Dose:**

The CDC recommends the additional dose of an mRNA COVID-19 vaccine be administered at least four weeks after a second dose of the Pfizer-BioNTech or Moderna vaccine. For people who received the Pfizer-BioNTech or Moderna COVID-19 vaccine series, a third dose of the same mRNA vaccine should be used if possible. If the same mRNA vaccine isn't available for the third dose administration or is unknown, either mRNA COVID-19 vaccine may be used. Currently, a second dose of the Janssen/Johnson & Johnson vaccine is not recommended and not covered by the most recent EUA update.

- We do not recommend (outside of a research study) the use of antibody titers to determine if patients should receive the third dose.
- Selection of patients with cancer to receive a third dose should be made based on the underlying cancer, therapy, and other immunocompromising conditions.
- Patients who have a history of COVID-19 following their initial vaccine series, should also receive a third dose (delayed >28 days post completed vaccine series and documented clearance of SARS-CoV-2 virus)

#### **Prevention Efforts Despite Third Dose:**

Although preliminary data show that a third dose can augment antibody titers in immunocompromised patients, cancer patients remain at higher risk for COVID-19 and associated complications. Vaccine responses, even with an additional dose, may not be sufficient to prevent infection. Therefore, despite receiving a third dose, patients should continue to maintain masking in public spaces (particularly indoors), and avoid crowds and large public gatherings. Limiting contact with those outside their household, particularly in indoor/poorly ventilated environments, is also important to prevent transmission. Although transmission can occur even in vaccinated individuals, cancer patients should avoid all unmasked interactions with unvaccinated individuals if possible.

#### **Prioritization if Local Supply Issues Occur:**

The above recommendations for a third dose are based on adequate vaccine supply, which is the case in the vast majority of regions in the United States. With adequate supply, we strongly endorse that patients with cancer who meet these eligibility criteria obtain the third dose where available and most convenient, including at local pharmacies, but would also prioritize allocation to cancer centers to assure ease of distribution to high-risk patients. In situations of limited vaccine availability, individual cancer centers and oncologists may need to prioritize a third dose to those patients who are least likely to respond to the standard 2-dose series such as:

- a) Hematopoietic cell transplant/cellular therapy recipients
- b) Patients with hematologic malignancies on active therapy
- c) Patients with solid tumor malignancies receiving active intravenous chemotherapy

**OVERVIEW:**

Large cohort studies have demonstrated that cancer patients are at high risk for COVID-19-associated complications.<sup>11-14</sup> As an at-risk population, there is a clear need for vaccinating these patients to avoid excess morbidity and mortality during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. In addition, since immunosuppressed patients may be sources of prolonged viral shedding and development of variants<sup>15,16</sup>, prioritizing vaccinations to these vulnerable patients may provide an additional societal benefit. Individuals with active cancer or with active, recent (<6 months), or planned cancer treatment should be considered highest priority to receive one of the currently available COVID-19 vaccines that have received emergency use authorization (EUA) by FDA [Pfizer/BioNTech vaccine (Comirnaty®) is now fully FDA approved for ≥ 16 years of age].<sup>17-19</sup> This document, while focusing on approved vaccines in the US, can also be used to support vaccination approaches in cancer patients using vaccines approved in other parts of the world.

The NCCN COVID-19 Vaccination Advisory Committee recommends that COVID-19 vaccines should be given to all cancer patients, as well as household contacts and caregivers, when they are eligible to receive the vaccine; the committee has no preference for any of the approved vaccines. Data from vaccine trials have demonstrated that vaccines decrease the incidence of COVID-19 disease and complications, and data suggest that these vaccines may additionally prevent SARS-CoV-2 infection and subsequent risk of transmission. However, due to early reports of less vaccine efficacy in cancer patients, patients and close contacts should continue to wear masks, maintain social distancing guidelines, and follow other recommendations for COVID-19 prevention even if vaccinated.

***Due to emerging data relating to vaccination efficacy in patients with active malignancy, recommendations are based on the expert opinion of the committee; as data continue to become available, our approach will be modified accordingly.*** Decisions about when to offer COVID-19 vaccines should also take into account the National Academies of Sciences, Engineering, and Medicine (NASEM) Framework for Equitable Allocation of COVID-19 Vaccine that includes: risk of infection, severe morbidity and mortality, excess burden of COVID-19 on specific communities, and transmission to others.<sup>20</sup> **The key principles are as follows:**

1. There are emerging data for these vaccines in patients with cancer, but generating data for these populations, especially in those receiving active cancer therapy, remains a priority. Despite gaps in knowledge about specific patient populations and treatments, we strongly recommend that patients with cancer receive vaccination as soon as eligible given their increased risk of morbidity and mortality from COVID-19.
2. Persons with active cancer are at increased risk of complications from SARS-CoV-2, and efforts to limit spread in high-risk patients at cancer centers is imperative. Cancer centers should be specified locations where vaccines should be allocated to allow safe delivery to these high-risk patients.
3. A simple and rapid approach to vaccination is important.
4. Vaccines should be offered to cancer patients in a manner to assure inclusion of racial/ethnic minorities, non-English-speaking patients, and other at-risk groups (e.g. patients with disabilities) to ensure equity in COVID-19 vaccine distribution; health care systems should make special efforts to take into consideration social vulnerability markers that have been demonstrated during this pandemic.

5. To date, there are no reports of increased risk for side effects of the COVID-19 vaccines in patients with cancer as compared to the general population.
6. Vaccine efficacy in the setting of cancer care and a weakened immune system is thought to be less robust than in the general population, particularly for hematologic malignancies. However, vaccination is strongly recommended for all eligible cancer patients.
7. Those immediately around patients under cancer care (e.g. spouses, household members) are the most likely to be sources of transmission and should be vaccinated as soon as possible.
8. The committee supports mandates for healthcare workers.

#### **VACCINE SAFETY AND EFFICACY IN CANCER PATIENTS:**

Cancer patients should be counseled that although these vaccines have been shown to be safe and effective in the general population, data on their effectiveness in immunosuppressed patients is emerging. The data on COVID-19 vaccine immunogenicity are mostly limited to measurement of post-vaccine antibody titers to the viral spike protein. Still, early data has demonstrated blunted antibody responses in patients with solid tumors and hematologic malignancies, particularly patients on active treatment;<sup>34-38</sup> data among other immunosuppressed populations also indicates more limited antibody responses.<sup>39</sup> Antibody responses are particularly poor among patients with hematologic malignancies, including those receiving monoclonal antibodies targeting CD20 (e.g. rituximab). Antibody responses should be interpreted with caution, as they are only a surrogate marker for vaccine protection. Some studies have demonstrated additional T-cell responses to vaccination,<sup>40</sup> although the strength and duration of neutralizing antibody responses or cellular immunity are not known at this point. Importantly, outcomes data (e.g. COVID-19 disease, hospitalization, death) among fully vaccinated cancer patients are not available. All cancer patients should receive education regarding the importance of following all [current prevention guidance post-vaccination](#). Eligible caregivers and household/close contacts should be strongly encouraged to get vaccinated. The committee supports vaccination mandates for healthcare workers (see [statement](#)).

There are no safety signals that suggest adverse events specifically among patients with cancer receiving currently available COVID-19 vaccines; although rare case reports have been reported in cancer populations.<sup>41</sup> Current SARS-CoV-2 mRNA vaccines (e.g. Pfizer/BioNTech, Moderna) do not contain live virus and do not pose an immediate safety risk for immunosuppressed patients. The available single dose SARS-CoV-2 viral vector (Adenovirus-type 26 [AdV-type 26]) vaccine (Janssen/Johnson & Johnson) is safe for use in immunosuppressed hosts, as the adenovirus vector has been modified to make it replication incompetent.<sup>21</sup> Although other vaccines are currently available in other parts of the world (e.g. Astra-Zeneca COVID-19 vaccine, Sputnik [AdV26, AdV5 vaccine], Covaxin [killed whole virus vaccine with adjuvant], Sinovac [killed whole virus vaccine]), they are not currently available for use in the U.S.

All three available vaccines (in the U.S.) have been shown to be safe in the general population, although post-vaccination arm soreness, fatigue, fever, and headache, among other side effects are not uncommon.<sup>17-19</sup> To date, only Pfizer/BioNTech mRNA vaccine (Comirnaty®) is fully approved by the FDA. Short-term safety of the Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors has been reported.<sup>33</sup> Anaphylaxis has been reported with both mRNA vaccines, although incidence is very low, ranging from 2.5-4.9 cases per million doses administered<sup>22</sup>; severe allergic responses have also been reported with the AdV-type 26 vector vaccine.

Although more data are required to evaluate the safety of COVID-19 vaccination in patients with cancer including those receiving immunotherapy, targeted regimens, and investigational therapies, the results so far show an acceptable safety profile of COVID-19 vaccination.

**Post-vaccine thrombosis:** The available single dose SARS-CoV-2 viral vector (AdV-type 26) vaccine (Janssen/Johnson & Johnson) has been associated with an exceedingly rare risk of thrombosis with low platelets after vaccination (Thrombosis with Thrombocytopenia syndrome [TTS]); similar findings have been linked to the Astra-Zeneca (AdV-type 26) vaccine.<sup>42</sup> The mechanism that causes TTS is not fully understood. To date there have been no associations between TTS and cancer patients, but patients who have a history of heparin-induced thrombocytopenia and/or thrombosis should be counseled to receive another vaccine.

**Post-vaccine lymphadenopathy and Imaging Studies in Cancer Patients:** Reactive lymphadenopathy has been reported in up to 16% of the patients following COVID-19 vaccination with the mRNA (Pfizer/BioNTech, Moderna) vaccines; this side effect has not been reported to date with the AdV-type 26 vector vaccine (Janssen/Johnson & Johnson).<sup>23-25</sup> To reduce the number of unwarranted biopsies, several reports with guidance on imaging studies have been published. Vaccination history and site of injection should be included in medical history to provide the radiologists with the clinical background for accurate interpretation. The Society of Breast Imaging recommends consideration of scheduling screening breast imaging 4-6 weeks following the completion of the COVID-19 vaccination, when possible.<sup>26</sup> Unilateral lymphadenopathy noted on chest CT may likely be reactive following the vaccine unless it persists beyond six weeks following the second dose of the vaccine<sup>27</sup>; abnormal FDG uptake with PET scanning has also been reported.<sup>28</sup> With the currently available data, we recommend delay of imaging studies by 4-6 weeks following the COVID-19 vaccine if it will not result in a delay that will affect patient outcomes. For patients whose scans cannot be delayed in relation to the vaccination, careful consideration of the clinical context should be made by the treating oncologists and radiologists when interpreting the imaging studies. For patients who have a history of breast cancer, the vaccine should be administered in the contralateral arm whenever possible.

#### **ANTIBODY TESTING POST-VACCINATION:**

Available vaccines have not been systematically evaluated in patients with active cancer or recipients of cellular therapy (hematopoietic cell transplant/chimeric antigen receptor T-cell) as these populations were mostly excluded from clinical trials; although both the Pfizer/BioNTech and Janssen/Johnson & Johnson vaccine clinical trials did include cancer patients. Assessment for long-term immunity after vaccination with serologic testing (against spike protein of SARS-CoV2) in the cancer population and the general population outside of the clinical trial are lacking, so utility of such post-vaccine testing is unclear. There is clear need for future vaccine trials to include cancer patients.

The correlation between antibody titers (against spike protein) and immunity as well as the duration of protection is not known at this time. Additionally, it is postulated that vaccine induced T-cell immunity may play a role in protection. Immunologic data from trials are still pending and at present standardized commercially available assays evaluating T-cell responses are lacking. Furthermore, the diversity of antibody tests, include non-vaccine targets such as the viral nucleocapsid, make interpretation of results even more complicated.<sup>29</sup> The FDA does not recommend routine post-vaccine antibody testing.<sup>43</sup> Antibody testing is complicated and may be difficult to interpret in the post-vaccination phase, but testing in select situations, such as part of research protocols can be considered; antibody testing if sent should target the spike protein (marker of vaccine response) and not the SARS-CoV-2 nucleocapsid

protein (marker of acute infection). Importantly, antibody testing should not be used to determine if patients should receive the recommended third dose of mRNA vaccines.

#### **IMPORTANCE OF COVID-19 VACCINATION AMONG PATIENTS WITH CANCER, THEIR HOUSEHOLD MEMBERS, AND THE GENERAL POPULATION:**

In prior versions of this guidance, patients with cancer were prioritized for vaccination based on a number of factors that included those with active cancer on treatment, those planned to start therapy, and those < 6 months of completion of therapy (excluding those receiving only hormonal therapy). The guidance also recommended consideration of older age and comorbidities that increase the risk of COVID-19-related morbidity and mortality (e.g. chronic lung, cardiovascular, or renal disease) and social and demographic factors such as poverty, limited access to healthcare, and underrepresented minorities. Although barriers to vaccine access still exist, the need for prioritization of cancer patients has been largely obviated by widespread vaccination throughout the country. Seen in this light, patients with cancer face two major obstacles regarding vaccination: lack of effective immune responses due to their underlying disease and/or therapy; and vaccine hesitancy in the general population that impedes the development of herd (community) immunity. Emerging data demonstrate that certain patients with cancer (e.g. those receiving B cell-depleting agents) may not have protective antibody titers following vaccination. Although we strongly continue to recommend that these patients be immunized because the vaccine may confer some protection against COVID-19, the most effective protection for specific immunocompromised patients with cancer is likely to be through a reduction of community spread of SARS-CoV-2 by widespread vaccination. **We also note the particular importance for eligible household members and other close contacts of patients with cancer to be immunized.**

***Vaccination of cancer patients enrolled/planning to enroll in clinical trials:*** Patients currently being treated on clinical trials, or considering enrollment on a clinical trial should not defer COVID-19 vaccination, or be ineligible for enrollment or continuation on a clinical trial because of COVID-19 vaccination, unless there is a specific scientific contraindication. The same should apply to COVID-19 antibody treatment. Clinical trials currently ongoing or nearing initiation should allow for COVID-19-related interventions without excluding candidacy or ongoing participation. The COVID-19 and Cancer Clinical Trials Working Group also recommended that patients with cancer enrolled in clinical trials should be prioritized for COVID-19 immunization, which should not affect clinical trial eligibility.<sup>44</sup>

#### **SOCIETAL CONSIDERATIONS:**

It is imperative that all patients have equitable access to the vaccines. The NASEM guidelines have recommended the incorporation of social vulnerability indices to mitigate health inequities that have clearly arisen during the COVID-19 pandemic.<sup>20</sup> Notably, similar to the general non-cancer population, Black/African American, Hispanic/Latino, and Native American patients with cancer have been observed to have increased risk of developing COVID-19.<sup>30</sup> Consequently, we encourage health systems to incorporate social vulnerability markers tailored to their populations to address the myriad of health inequities that have arisen during this pandemic.<sup>31</sup> In addition, patients who may not have access to electronic health record platforms or email should be considered when vaccine invitation and scheduling are being operationalized. Special efforts should also be made to engage and incorporate those patients with limited English proficiency. Finally, health systems are encouraged to collect—to the extent possible—both race-ethnic and socioeconomic data for patients who receive the vaccine, so that these data can be periodically reviewed, and if inequities develop, aggressively addressed.

**POST-VACCINE PREVENTION:**

Recommendations from the CDC for loosening restrictions for the general public  $\geq 2$  weeks after completion of COVID-19 vaccination<sup>32</sup> (2 weeks post second dose for Pfizer/BioNTech and Moderna, 2 weeks after first dose of Janssen/Johnson & Johnson), may not be reflective of what is best for the cancer community. The committee strongly recommends continued vigilance for cancer patients. As cancer patients are at increased risk for COVID-19 complications and may have less protection from available vaccines, patients should continue to wear masks, maintain social distancing, avoid crowds and follow guidelines and other pre-vaccine recommendations for COVID-19 prevention. Efforts to protect patients should also expand to families, caregivers and household contacts, where targeted vaccination approaches can help assure patients are less likely to acquire SARS-CoV-2 from those closest to them.<sup>45</sup> These prevention strategies should continue even if patients receive a recommended third dose of the mRNA vaccines.

**PRIORITIZATION AMONG CANCER PATIENTS IN SETTINGS OF LIMITED VACCINE AVAILABILITY:**

Currently in the U.S. vaccine supply is not an issue. COVID-19 vaccine availability varies in different regions of the world, and limitations exist in ability to vaccinate large populations efficiently (e.g. rural vs. urban communities). These realities may still necessitate prioritization of an order in which patients with cancer are offered immunization. This prioritization must be as evidence-based but also value-based as possible; even so, debate and disagreements exist. In situations of vaccine shortage, risk factors for COVID-19–related morbidity and mortality (e.g. advanced age, chronic lung disease, cardiovascular disease) and cancer-specific factors should be considered in prioritization. Those with active cancer and/or therapy should be prioritized over those who completed therapy and those without evidence of disease. For those addressing shortages, the committee cannot issue a recommendation on prioritization based on chemotherapy, surgery, radiation, targeted therapy, or immunotherapy; however, patients without active cancer who are only receiving hormonal therapy would have lower prioritization.

Prioritization is challenging to develop when considering the diverse population of patients with their varied comorbidities, demographic and social factors known to increase risk of COVID-19 acquisition, morbidity, and/or mortality. The following criteria can be used to help determine local guidance to consider when developing such decisions\*:

- 1) Prioritize patients with active cancer on treatment (*including hematopoietic and cellular therapy*), those planned to start treatment, and those immediately (<6 months) post-treatment, except those receiving only hormonal therapy.
- 2) Consider additional risk factors for such patients and other factors linked to adverse COVID-19 complications including, but not limited to:
  - a. Patients with advanced age (e.g.  $\geq 65$  years of age)
  - b. Patients with comorbidities (e.g. chronic pulmonary, cardiovascular, or renal disease)
  - c. Social and demographic factors that include poverty, limited access to health care, and underrepresented minorities

\*The current vaccine recommendations and prioritization guidelines will be updated regularly based on availability of new data. There are important gaps in knowledge on vaccine immunogenicity in specific patients with cancer and therapies. We will learn more about specific therapies that limit vaccine efficacy and would warrant vaccine delay. The durability of vaccine protection is being investigated in the general population and is shown to be attenuated in immunocompromised patients with cancer.

**REFERENCES:**

1. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. *N Engl J Med*. 2021;385(7):661-662.
2. Ghione P, Gu JJ, Attwood K, et al. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell directed therapies. *Blood*. 2021.
3. Griffiths EA, Segal BH. Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution. *Cancer Cell*. 2021;39(8):1045-1047.
4. Addeo A, Shah PK, Bordry N, et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. *Cancer Cell*. 2021;39(8):1091-1098 e1092.
5. Thakkar A, Gonzalez-Lugo JD, Goradia N, et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. *Cancer Cell*. 2021;39(8):1081-1090 e1082.
6. Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. *Blood*. 2021;137(23):3165-3173.
7. Stampfer SD, Goldwater MS, Jew S, et al. Response to mRNA vaccination for COVID-19 among patients with multiple myeloma. *Leukemia*. 2021.
8. Terpos E, Trougakos IP, Gavriatopoulou M, et al. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. *Blood*. 2021;137(26):3674-3676.
9. Van Oekelen O, Gleason CR, Agte S, et al. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. *Cancer Cell*. 2021;39(8):1028-1030.
10. Pimpinelli F, Marchesi F, Piaggio G, et al. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution. *J Hematol Oncol*. 2021;14(1):81.
11. Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. *Lancet* 2020;395(10241):1907-1918.
12. Robilotti EV, Babady NE, Mead PA, et al. Determinants of COVID-19 disease severity in patients with cancer. *Nat Med* 2020;26(8):1218-1223.
13. Lee LY, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. *Lancet* 2020;395(10241):1919-1926.
14. Sharma A, Bhatt NS, St Martin A, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. *Lancet Haematol*. 2021. Mar;8(3):e185-e193. doi: 10.1016/S2352-3026(20)30429-4. Epub 2021 Jan 19.
15. Aydililo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer. *N Engl J Med*. 2020;383(26):2586-2588.
16. McCarthy KR, Rennick LJ, Nambulli S, et al. Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. *Science*. 2021. Feb 3;eabf6950. doi: 10.1126/science.abf6950.

17. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Eng J Med* 2020;383(27):2603-2615.
18. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Eng J Med*. 2020 Dec 30;NEJMoa2035389.
19. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting February 26, 2021: FDA Briefing Document. Accessed March 7, 2021. <https://www.fda.gov/media/146217/download>
20. Gaile H, Foege W, Brown L, Kahn B, eds. A Framework for Equitable Allocation of Vaccine for the Novel Coronavirus. National Academy of Sciences, Engineering, and Medicine; August 2020. Accessed January 14, 2021. <https://www.nationalacademies.org/our-work/a-framework-for-equitable-allocation-of-vaccine-for-the-novel-coronavirus>.
21. Sadoff J, Le Gars M, Shukarev G, et al. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. *N Engl J Med*. 2021. Jan 13;NEJMoa2034201. doi: 10.1056/NEJMoa2034201.
22. Shimabukuro TT, Cole M, Su JR. Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021. *JAMA*. 2021. Feb 12. doi: 10.1001/jama.2021.1967.
23. Centers for Disease Control and Prevention. Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Pfizer-BioNTech COVID-19 Vaccine. December 13, 2020. Accessed March 6, 2021 <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html>
24. Centers for Disease Control and Prevention. Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Moderna COVID-19 Vaccine. December 20, 2020. Accessed March 6, 2021 <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/reactogenicity.html>
25. Centers for Disease Control and Prevention. Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Janssen COVID-19 Vaccine. February 26, 2021. Accessed March 6, 2021 <https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/reactogenicity.html>
26. Grimm L, Destounis S, Dogan B, et al. Society of Breast Imaging:SBI Recommendations for the Management of Axillary Adenopathy in Patients with Recent COVID-19 Vaccination. Accessed on March 8, 2021 <https://www.sbi-online.org/Portals/0/Position%20Statements/2021/SBI-recommendations-for-managing-axillary-adenopathy-post-COVID-vaccination.pdf>
27. Lehman CD, Mendoza DP, Succi MD, et al. Unilateral Lymphadenopathy Post COVID-19 Vaccination: A Practical Management Plan for Radiologists Across Specialties. *Radiology* 2021. epub March 3 2021 <https://doi.org/10.1016/j.jacr.2021.03.001>
28. Doss M, Nakhoda SK, Li Y, Yu JQ. COVID-19 Vaccine-Related Local FDG Uptake. *Clin Nucl Med*. 2021. Mar 4. doi: 10.1097/RLU.0000000000003634.
29. Lumley SF, Wei J, O'Donnell D, et al. The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers. *Clin Infect Dis*. 2021. Jan 6:ciab004. doi: 10.1093/cid/ciab004.
30. Potter D, Riffon M, Kakamada S, et al. Disproportionate impact of COVID-19 disease among racial and ethnic minorities in the U.S. cancer population as seen in CancerLinQ Discovery data. *J Clin Oncol* 2020;38 (suppl 29; abstr 84).

31. Schmidt H, Gostin LO, Williams, MA. Is it lawful or ethical to prioritize racial minorities for COVID-19 vaccines? *JAMA* 2020;324(20):2023-2024.
32. Centers for Disease Control and Prevention. Interim Public Health Recommendations for Fully Vaccinated People. March 8, 2021. Accessed on March 10, 2021  
<https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated-guidance.html>
33. Waissengrin B, Agbarya A, Safadi E, et al. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. *Lancet Oncol*. 2021 May;22(5):581-583. doi: 10.1016/S1470-2045(21)00155-8.
34. Monin L, Laing AG, Muñoz-Ruiz M, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. *Lancet Oncol*. 2021 Apr 27;22(6):765–78. doi: 10.1016/S1470-2045(21)00213-8.
35. Bird S, Panopoulou A, Shea RL, et al. Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. *Lancet Haematol*. 2021 Jun;8(6):e389-e392. doi: 10.1016/S2352-3026(21)00110-1.
36. Terpos E, Trougakos IP, Gavriatopoulou M, et al. Low Neutralizing Antibody Responses Against SARS-CoV-2 in Elderly Myeloma Patients After the First BNT162b2 Vaccine Dose. *Blood*. 2021 Apr 16:16:1011904. doi: 10.1182/blood.2021011904.
37. Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia. *Blood*. 2021 Apr 16:16:1011568. doi: 10.1182/blood.2021011568.
38. Shroff RT, Chalasani P, Wei R, et al. Immune Responses to COVID-19 mRNA Vaccines in Patients with Solid Tumors on Active, Immunosuppressive Cancer Therapy. *medRxiv* [Preprint]. 2021 May 14:2021.05.13.21257129. doi: 10.1101/2021.05.13.21257129.
39. Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. *JAMA*. 2021 Jun 1;325(21):2204-2206. doi: 10.1001/jama.2021.7489.
40. Monin L, Laing AG, Muñoz-Ruiz M, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. *Lancet Oncol*. 2021 Apr 27;22(6):765–78. doi: 10.1016/S1470-2045(21)00213-8.
41. Au L, Fendler A, Shepherd STC, et al. Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2. *Nat Med*. 2021 May 26. doi: 10.1038/s41591-021-01387-6.
42. Hunter, Paul R., Thrombosis after covid-19 vaccination. *BMJ* 2021;373:n958.  
doi: <https://doi.org/10.1136/bmj.n958>.
43. U.S. Food and Drug Administration. Antibody (Serology) Testing for COVID-19: Information for Patients and Consumers. Accessed on June 3, 2021 <https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/antibody-serology-testing-covid-19-information-patients-and-consumers>.
44. Desai A, Gainor JF, Hegde A, et al. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials [published correction appears in *Nat Rev Clin Oncol*. 2021 Mar 23]. *Nat Rev Clin Oncol*. 2021;18(5):313-319. doi:10.1038/s41571-021-00487-z.

45. Woodfield MC, Pergam SA, Shah PD. Cocooning against COVID-19: The argument for vaccinating caregivers of patients with cancer. *Cancer*. 2021 Apr 23. doi: 10.1002/cncr.33598.

46. Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States. Coadministration with other vaccines. Accessed on July 14, 2021 <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#Coadministration>.

###

*The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 31 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. By defining and advancing high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers around the world.*

*NCCN resources are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches. Any clinician seeking to apply or consult NCCN resources is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. NCCN makes no representations or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their application or use in any way.*

## NCCN COVID-19 Vaccination Advisory Committee

---

**\*Steven Pergam, MD, MPH (Co-Leader)**

Infectious Disease  
Fred Hutchinson Cancer Research Center/  
Seattle Cancer Care Alliance

**\*Lindsey Robert Baden, MD (Co-Leader)**

Infectious Disease  
Dana-Farber/Brigham and Women's  
Cancer Center

**\*Brahm Segal, MD (Co-Leader)**

Infectious Disease  
Roswell Park Comprehensive Cancer Center

**\*Gregory Abel, MD, MPH**

Medical Oncology, Ethics  
Dana-Farber/Brigham and Women's  
Cancer Center

**Kerin Adelson, MD**

Medical Oncology  
Yale Cancer Center/Smilow Cancer Hospital

**\*Craig Bunnell, MD, MPH, MBA**

Medical Oncology  
Dana-Farber/Brigham and Women's  
Cancer Center

**\*Pelin Cinar, MD, MS**

Medical Oncology  
UCSF Helen Diller Family  
Comprehensive Cancer Center

**\*Sanjeet Dadwal, MD**

Infectious Disease  
City of Hope National Medical Center

**John Glaspy, MD**

Hematology Oncology  
UCLA Jonsson Comprehensive Cancer Center

**\*Ayad Hamdan, MD**

Hematology  
UC San Diego Moores Cancer Center

**Aparna Hegde, MD**

Hematology Oncology  
O'Neal Comprehensive Cancer Center at UAB

**James Helstrom, MD, MBA**

Surgical Oncology  
Fox Chase Cancer Center

**Paul Hendrie, MD, PhD**

Hematology  
Fred Hutchinson Cancer Research Center/  
Seattle Cancer Care Alliance

**Ephraim Hochberg, MD**

Hematology Oncology  
Massachusetts General Hospital  
Cancer Center

**Carol Ann Huff, MD**

Hematology Oncology  
The Sidney Kimmel Comprehensive  
Cancer Center at Johns Hopkins

**Michael Hurwitz, MD, PhD**

Medical Oncology  
Yale Cancer Center/Smilow Cancer Hospital

**Matt Kalaycio, MD**

Hematology Oncology  
Case Comprehensive Cancer Center/  
University Hospitals Seidman Cancer Center and  
Cleveland Clinic Taussig Cancer Institute

**Robert Keenan, MD, MMM**

Surgical Oncology  
Moffitt Cancer Center

**\*Nikhil I. Khushalani, MD**

Medical Oncology  
Moffitt Cancer Center

**Robert McWilliams, MD**

Medical Oncology  
Mayo Clinic Cancer Center

**Daniel Mulkerin, MD**

Medical Oncology  
University of Wisconsin Carbone Cancer Center

**\*Sirisha Narayana, MD**

Internal Medicine, Ethics  
UCSF Helen Diller Family  
Comprehensive Cancer Center

**William Nelson, MD, PhD**

Medical Oncology  
The Sidney Kimmel Comprehensive  
Cancer Center at Johns Hopkins

**\*Esperanza Papadopoulos, MD**

Hematology Oncology  
Memorial Sloan Kettering Cancer Center

**Thomas Prebet, MD, PhD**

Hematology  
Yale Cancer Center/Smilow Cancer Hospital

**Tom Purcell, MD, MBA**

Medical Oncology  
University of Colorado Cancer Center

**\*Gregory Riely, MD, PhD**

Medical Oncology  
Memorial Sloan Kettering Cancer Center

**\*Jennifer Saullo, MD**

Infectious Disease  
Duke Cancer Institute

*\*Writing Committee***Sumit Shah, MD, MPH**

Medical Oncology  
Stanford Cancer Institute

**Lawrence Shulman, MD**

Medical Oncology  
Abramson Cancer Center at the  
University of Pennsylvania

**John Sweetenham, MD**

Hematology Oncology, Internal Medicine  
UT Southwestern Simmons  
Comprehensive Cancer Center

**\*Holly Tabor, PhD**

Ethics  
Stanford Medicine

**\*Tina Q. Tan, MD**

Pediatric Infectious Disease  
Northwestern Medicine  
Ann & Robert H. Lurie  
Children's Hospital of Chicago

**Ronald Walters, MD, MBA, MHA**

Medical Oncology  
The University of Texas  
MD Anderson Cancer Center

**Alison Walker, MD, MBA**

Hematology  
The Ohio State University Comprehensive  
Cancer Center-James Cancer Hospital  
and Solove Research Institute

**\*Andrea Zimmer, MD**

Infectious Disease, Internal Medicine  
University of Nebraska Medical Center

**NCCN****\*Robert W. Carlson, MD****\*Wui-Jin Koh, MD**

Jessica Sugalski, MPPA